Endurant Capital Management LP reduced its position in Stryker Co. (NYSE:SYK) by 28.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 17,867 shares of the medical technology company’s stock after selling 7,237 shares during the quarter. Endurant Capital Management LP’s holdings in Stryker were worth $2,767,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors and hedge funds have also recently modified their holdings of SYK. Sei Investments Co. raised its position in shares of Stryker by 26.8% in the 3rd quarter. Sei Investments Co. now owns 41,104 shares of the medical technology company’s stock worth $5,838,000 after buying an additional 8,696 shares during the period. New York State Common Retirement Fund raised its position in Stryker by 1.1% in the third quarter. New York State Common Retirement Fund now owns 1,106,000 shares of the medical technology company’s stock valued at $157,074,000 after purchasing an additional 11,800 shares during the period. Advisors Asset Management Inc. raised its position in Stryker by 11.8% in the third quarter. Advisors Asset Management Inc. now owns 27,989 shares of the medical technology company’s stock valued at $3,975,000 after purchasing an additional 2,948 shares during the period. Buckingham Capital Management Inc. raised its position in Stryker by 9.4% in the third quarter. Buckingham Capital Management Inc. now owns 10,521 shares of the medical technology company’s stock valued at $1,494,000 after purchasing an additional 905 shares during the period. Finally, Macquarie Group Ltd. raised its position in Stryker by 3.5% in the third quarter. Macquarie Group Ltd. now owns 110,720 shares of the medical technology company’s stock valued at $15,724,000 after purchasing an additional 3,700 shares during the period. 75.71% of the stock is currently owned by institutional investors and hedge funds.
Shares of Stryker stock opened at $167.51 on Monday. The stock has a market capitalization of $62,756.28, a PE ratio of 62.50, a PEG ratio of 2.41 and a beta of 0.70. Stryker Co. has a 52-week low of $129.82 and a 52-week high of $170.00. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.59 and a current ratio of 2.29.
Stryker (NYSE:SYK) last posted its quarterly earnings results on Tuesday, January 30th. The medical technology company reported $1.96 EPS for the quarter, topping the Zacks’ consensus estimate of $1.95 by $0.01. The business had revenue of $3.47 billion during the quarter, compared to the consensus estimate of $3.42 billion. Stryker had a return on equity of 24.56% and a net margin of 8.20%. The company’s revenue for the quarter was up 9.9% compared to the same quarter last year. During the same period last year, the firm earned $1.78 earnings per share. research analysts predict that Stryker Co. will post 7.12 EPS for the current year.
The company also recently declared a quarterly dividend, which will be paid on Monday, April 30th. Investors of record on Thursday, March 29th will be paid a $0.47 dividend. The ex-dividend date is Wednesday, March 28th. This represents a $1.88 dividend on an annualized basis and a yield of 1.12%. Stryker’s dividend payout ratio (DPR) is 70.15%.
In other Stryker news, VP William E. Berry, Jr. sold 1,306 shares of Stryker stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $164.42, for a total value of $214,732.52. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Yin C. Becker sold 23,221 shares of Stryker stock in a transaction that occurred on Friday, March 9th. The shares were sold at an average price of $165.96, for a total value of $3,853,757.16. Following the completion of the transaction, the vice president now owns 10,499 shares of the company’s stock, valued at $1,742,414.04. The disclosure for this sale can be found here. Insiders sold 43,611 shares of company stock valued at $7,178,719 over the last quarter. Insiders own 7.40% of the company’s stock.
Several research analysts have commented on the company. Needham & Company LLC reissued a “hold” rating on shares of Stryker in a research report on Wednesday, January 31st. Piper Jaffray Companies reissued a “buy” rating and issued a $170.00 price objective on shares of Stryker in a research report on Wednesday, January 31st. Cantor Fitzgerald reissued a “hold” rating and issued a $163.00 price objective on shares of Stryker in a research report on Tuesday, January 30th. Robert W. Baird raised Stryker from a “neutral” rating to an “outperform” rating in a research report on Friday, November 24th. Finally, Guggenheim reissued a “buy” rating on shares of Stryker in a research report on Wednesday, January 31st. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and sixteen have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $164.76.
ILLEGAL ACTIVITY NOTICE: “Endurant Capital Management LP Cuts Position in Stryker Co. (SYK)” was published by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are accessing this piece of content on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright laws. The original version of this piece of content can be viewed at https://www.thelincolnianonline.com/2018/03/19/endurant-capital-management-lp-cuts-position-in-stryker-co-syk.html.
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.